ARTICLE | Clinical News

Single-Dose Sufentanil NanoTab: Phase III started

October 12, 2015 7:00 AM UTC

AcelRx began the open-label, U.S. Phase III SAP302 trial to evaluate a single dose of 30 ug sublingual ARX-04 in about 40 adult emergency room patients. Earlier this year, the company received a $17 m...